Net Cash Provided by (Used in) Financing Activities in USD of Acrivon Therapeutics, Inc. from 2021 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Acrivon Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2021 to Q1 2025.
  • Acrivon Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was -$343K, a 99.4% decline year-over-year.
  • Acrivon Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $121M.
  • Acrivon Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$1.55M, a 102% decline from 2022.
  • Acrivon Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $102M, a 9.37% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Acrivon Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$343K -$171K -99.4% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q1 2024 -$172K Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14

Acrivon Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $121M +$123M Jan 1, 2024 Dec 31, 2024 10-K 2025-03-27
2023 -$1.55M -$103M -102% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-27
2022 $102M -$10.5M -9.37% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $112M Jan 1, 2021 Dec 31, 2021 10-K 2023-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.